NORD and Medlive Continue Partnership to Transform Rare Disease Medical Education

NORD and Medlive Extend a Meaningful Partnership

On January 6, 2026, Medlive announced that the National Organization for Rare Disorders (NORD) has chosen it as its exclusive Continuing Medical Education (CME) partner once again. This decision underscores a mutual commitment to improving medical education focused on rare diseases to enhance patient care significantly.

The partnership, which has been in effect for over six years, aims to broaden the access to crucial educational resources for healthcare professionals. Through a broad array of digital programming, it has successfully engaged over 76,000 clinicians and caregivers, with impressive feedback indicating that 93% of physicians noted a positive shift in their clinical practices. Many patients reported improved communication with their healthcare providers due to this initiative.

Pam Gavin, NORD’s Chief Executive Officer, expressed enthusiasm about the renewed partnership: "Medlive demonstrates a deep understanding of the essential needs of the rare disease community, such as creating tools for timely diagnosis and effective care strategies. Their innovative approach makes them an integral partner in our mission."

The extension of the partnership promises to introduce new measures based on real-world data aimed at generating tangible evidence of care improvements. This initiative allows better sharing of outcomes through presentations at prominent scientific meetings, reflecting a commitment to continuous education and learning. Moreover, innovative educational formats are set to be developed, which will meet the emerging needs of those impacted by rare diseases.

Robert Rosenbloom, Chief Executive Officer of Medlive, emphasized the importance of this partnership, stating, "NORD has always been at the forefront of raising awareness and education regarding rare diseases. By continuing our collaboration, we aim to enhance connections between clinicians, patients, and advocates, ultimately leading to better outcomes for those affected by rare conditions."

The collaboration also aims to push the boundaries of disease-specific education beyond community-level efforts, ensuring that valuable educational resources reach a broader audience, thus impacting more individuals facing rare diseases throughout the nation.

NORD has been a committed advocate for the over 30 million Americans living with rare diseases since its founding in 1983. Working in tandem with over 350 patient organizations, it aims not only to drive progress in research and care but also in the policy concerning rare diseases.

This partnership is crucial for raising awareness around rare diseases and ensuring that both education and resources are effectively disseminated. Explore NORD's vast array of educational offerings on their dedicated page at medlive.com/nord, which houses a treasury of vital resources curated to improve patient care in the realm of rare diseases.

In conclusion, the continuous commitment of NORD and Medlive exemplifies how collaborative efforts can lead to a more effective healthcare landscape, especially for those battling rare diseases. By bridging the gap between education and practical care solutions, they are helping to transform patient outcomes, ensuring that those affected are not isolated in their journeys but supported by informed and engaged healthcare providers.